Renalytix AI PLC Proposed dual-listing on Nasdaq (1244N)
18 May 2020 - 4:00PM
UK Regulatory
TIDMRENX
RNS Number : 1244N
Renalytix AI PLC
18 May 2020
This announcement contains inside information
Renalytix AI plc
("RenalytixAI", the "Company")
Proposed dual-listing on Nasdaq
Renalytix AI plc (LSE : RENX ), a commercial-stage artificial
intelligence-enabled in vitro diagnostics company, focused on
optimizing clinical management of kidney disease to drive improved
patient outcomes and lower healthcare costs , announces that it has
confidentially submitted a draft registration statement on Form F-1
with the Securities and Exchange Commission (the "SEC") relating to
a proposed dual-listing and public offering of American Depositary
Shares, each of which will represent one or a number of the
Company's ordinary shares, on the Nasdaq Stock Market (the
"Offering").
The number of securities to be offered and the price for the
proposed Offering have not yet been determined. The Offering is
expected to commence after the SEC completes its review process,
subject to market and other conditions . Shareholders and potential
investors should note that the potential Offering may or may not
proceed.
This press release is being made pursuant to, and in accordance
with, Rule 135 under the Securities Act of 1933, as amended (the
"Securities Act"). This press release does not constitute an offer
to sell or the solicitation of an offer to buy securities, and
shall not constitute an offer, solicitation or sale in any
jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities laws of that jurisdiction. Any offers, solicitations or
offers to buy, or any sales of securities will be made in
accordance with the registration requirements of the Securities
Act.
For further information, please contact:
Renalytix AI plc www.renalytixai.com
James McCullough, CEO Via Walbrook PR
Stifel (Nominated Adviser) Tel: 020 7710 7600
Alex Price / Nicholas Moore
Walbrook PR Limited Tel: 020 7933 8780 or renalytix@walbrookpr.com
Paul McManus / Lianne Cawthorne Mob: 07980 541 893 / 07584
391 303
The person responsible for arranging the release of this
announcement on behalf of the Company is James McCullough, CEO of
Renalytix AI plc.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCKZGMKNNGGGZM
(END) Dow Jones Newswires
May 18, 2020 02:00 ET (06:00 GMT)
Renalytix (LSE:RENX)
Historical Stock Chart
From Apr 2024 to May 2024
Renalytix (LSE:RENX)
Historical Stock Chart
From May 2023 to May 2024